英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
dissapearance查看　dissapearance　在百度字典中的解释百度英翻中〔查看〕
dissapearance查看　dissapearance　在Google字典中的解释Google英翻中〔查看〕
dissapearance查看　dissapearance　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Onetime CFO Resigns as ImClone CEO - cfo. com
    Daniel Lynch has resigned as chief executive officer and director of ImClone Systems, the company made famous in part by Martha Stewart, who was jailed for lying about her investment in the drug maker
  • Dan Lynch – Delphia Therapeutics
    Previously, Dan served as CEO and CFO of ImClone Systems Corporation As CEO, he led the company through a significant turnaround, helping to restore its reputation and secure FDA approval of the novel cancer treatment ERBITUX® (Cetuximab)
  • Chutes Ladders: ImClone CEO Lynch resigns | Fierce Biotech
    ImClone CEO Daniel S Lynch announced his resignation on Thursday Lynch had been CEO since April 2003, when he replaced Harlan Waksal
  • ImClone Systems CEO Daniel S. Lynch Resigns, Interim Chief . . .
    ImClone Systems Inc , the company shaken by insider trading charges that ensnared domestic diva Martha Stewart, announced Thursday that its chief executive has resigned The CEO, Daniel S Lynch, also resigned as a director, effectively immediately, by mutual agreement of the board, the company said Dr
  • Daniel S. Lynch - Beeline Medicines
    Earlier in his career, Mr Lynch served as Chief Executive Officer and Chief Financial Officer of ImClone Systems, where he led the company through a significant turnaround and secured FDA approval of the novel cancer therapy Erbitux
  • ImClone chief resigns, company begins external search for . . .
    ImClone Systems CEO Daniel Lynch has resigned and will be replaced, on an interim basis, by chief scientific officer Philip Frost, the New York-based biotech company announced today
  • Daniel Lynch - Venture Partner @ Third Rock Ventures . . .
    In addition to his role at Third Rock, Daniel serves as Executive Chairman of the Board of Directors at BIND Therapeutics, Nimbus Discovery and RaNA Therapeutics Prior to joining Third Rock, Daniel served as Chief Executive and Chief Financial Officer at ImClone Systems Corp





中文字典-英文字典  2005-2009